Presbia PLC (NASDAQ:LENS), an ophthalmic device company and leader in
near-vision restoration that has developed and is currently marketing
the Presbia Flexivue Microlens™, a proprietary optical lens implant for
treating presbyopia, announced today that Todd Cooper, President and
CEO, is scheduled to present at the Jefferies 2017 Global Healthcare
Conference on Tuesday, June 6th, at 11:30 a.m. ET. The
Conference will take place in New York at the Grand Hyatt from June 6 to
9, 2017. Mr. Cooper will be available for one-on-one meetings at the
The presentation will provide an update on the status of the U.S.
clinical trial. "Presbia plans on submitting the fourth and final module
of the IDE study to the FDA in Q4, which is a major milestone towards
approval of the Presbia Flexivue Microlens™ in the U.S.," said Mr.
Information provided and statements contained in this press release that
are not purely historical are forward-looking statements. Such
forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward looking in nature may involve risks and uncertainties.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Although
Presbia believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to
have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law,
Presbia also disclaims any obligation to update its view of any such
risks or uncertainties or to announce publicly the result of any
revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens™
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170530006468/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media